ArQule, Inc.
ArQule Presents Three Studies at AACR 100th Annual Meeting 2009
Published in Cancer Weekly, May 5th, 2009
These pre-clinical studies include two ArQule compounds in clinical development: ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, and ARQ 621, a novel inhibitor of the Eg5 kinesin motor protein.
Summaries of these studies are presented below. Summaries of ArQule presentations at AACR ARQ 197 / c-Met Inhibition 1. Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-05-05)
More Articles from Cancer Weekly
- Brain Cancer
Study results from Brain Tumor Center provide new insights into brain cancer - Cancer Gene Therapy
Research conducted at University of Marburg, Medical Department has updated our knowledge about cancer gene therapy - Cancer Gene Therapy
Research reports on cancer gene therapy from I. Gentschev and colleagues provide new insights - Cancer Vaccines
Newly published study shows that re-treatment with PegasysŪ (peginterferon alfa-2a) provides hepatitis C patients with a second chance for a cure - Cancer Vaccines
Reports from Baylor College of Medicine, College of Medicine describe recent advances in cancer vaccines - Cancer Vaccines
Researchers from University of Georgia report details of new studies and findings in the area of cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
